Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma | Synapse
July 22, 2015
Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma
Key Points
Key points are not available for this paper at this time.
Abstract
These studies suggest that further evaluation of the optimal MAPK targeting approach is warranted to extend therapeutic options in CML.